title: Testosterone Deficiency and Testosterone Treatment in Older Men.
abstract: Frailty is a clinical condition related to changes in metabolism, to sarcopenia, and to decline in muscle mass and strength, bone mineral density, and physical function with aging. The pathophysiology of frailty is multifactorial and associated with comorbidities. Testosterone is implicated in regulating metabolic functions, maintenance of muscle and bone, and inhibition of adipogenesis. In older individuals, reduced testosterone is thought to contribute to an altered state of metabolism, loss of muscle and bone, and increased fat, leading to sarcopenia, sarcopenic obesity, and frailty. While no direct relationship between testosterone deficiency (commonly known as hypogonadism) and frailty has been established (due to the multifactorial nature of frailty), clinical evidence suggests that testosterone deficiency is associated with increased sarcopenia and obesity. Testosterone treatment in frail older men with limited mobility and with testosterone deficiency improved insulin resistance, glucose metabolism, and body composition. These changes contribute to better physical function and improved quality of life. Because frailty increases disability, comorbidities, and the risk of hospitalization, institutionalization, and mortality in older men, it is warranted to explore the potential usefulness of testosterone treatment in frail men with hypogonadism in order to attenuate the progression of sarcopenia and frailty. In this paper, we will discuss the impact of testosterone deficiency on frailty and the potential role of testosterone treatment in ameliorating and reducing the progression of frailty. Such an approach may reduce disability and the risk of hospitalization and increase functional independence and quality of life.
authors.affiliation: Global Medical Affairs Andrology, Bayer AG, Berlin, Germany.
authors.forename: Farid
authors.initials: F
authors.lastname: Saad
authors.forename: Gabriele
authors.initials: G
authors.lastname: Röhrig
authors.forename: Stephan
authors.initials: S
authors.lastname: von Haehling
authors.forename: Abdulmaged
authors.initials: A
authors.lastname: Traish
mesh_terms: D000058:Accidental Falls / Q000517:prevention & control; D000339:Affect / Q000187:drug effects; D000368:Aged; D000375:Aging / Q000502:physiology* / Q000523:psychology; D000740:Anemia / Q000188:drug therapy / Q000209:etiology; D001823:Body Composition / Q000187:drug effects; D015519:Bone Density / Q000187:drug effects; D003071:Cognition / Q000187:drug effects; D016330:Frail Elderly; D006801:Humans; D007333:Insulin Resistance; D008297:Male; D053580:Muscle Strength / Q000187:drug effects; D009765:Obesity / Q000150:complications; D011788:Quality of Life; D055948:Sarcopenia / Q000188:drug therapy / Q000209:etiology / Q000503:physiopathology; D013739:Testosterone / Q000172:deficiency* / Q000627:therapeutic use*
chemical_list: D013739:Testosterone